Chastened Innate Returns Lumoxiti Rights To AZ
Struggled To Commercialize Hairy Cell Leukemia Drug
Executive Summary
The French firm gave back the rights to Lumoxiti on the same day the drug got a thumbs up from the CHMP after struggling to market the rare leukemia drug in the US.
You may also be interested in...
AstraZeneca Finds Two More Potential Partners For Imfinzi
Adding oleclumab and monalizumab to the PD-L1 inhibitor improved PFS, while another study showed improved real-world outcomes.
Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Innate Pharma's Expanded IO AstraZeneca Deal Jump-Starts US Ambitions
France's Innate Pharma gets a boost to its plans to become a fully integrated biotech by forging a long-term immuno-oncology development partnership with AstraZeneca, and the setting up of a commercialization team in the US.